Das Medizinportal
Menü

Literatur:

Die organerhaltende Nierentumorenukleation: Indikationsstellung insbesondere auch bei 
komplexen Tumoren und älteren Patienten (S.10–16)
Caroline Kauffmann, David Pfister, Axel Heidenreich

  1. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC; European Association of Urology Guideline Group. EAU guidelines on renal cell carcinoma: the 2017 update
  2. 2000 TSUI, K. H. ; SHVARTS, O. ; SMITH, R. B. ; FIGLIN, R. A. ; DEKERNION, J. B. ; BELLDEGRUN, A.: Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. In: J Urol 163 (2000), Nr. 4, S. 1090–5; quiz 1295
  3. Poulakis V, Witzsch U, Vries R de et al (2003) Quality of life after surgery for localized renal cell carcinoma: comparison between radical nephrectomy and nephron-sparing surgery. Urology 62: 814–817
  4. Patard JJ, Shvarts O, Lam JS et al (2004) Sefety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 171: 2181–2185
  5. Hellenthal NJ, Mansour AM, Hayn MH, Schwaab T (2011) Renal cell carcinoma in octogenarians: nephron sparing surgery should remain the standard of care. J Urol 185: 415–420
  6. Miller DC, Schonlau M, Litwin MS et al (2008) Urologic Diseases in America Project. Renal and cardiovascular morbidity after partial or radical nephrectomy. Cancer 112: 511–520
  7. Becker F, Siemer S, Hack M et al (2006) Excellent long term cancer control with elective nephron sparing surgery for selected renal cell carcinomas measuring more than 4 cm. Eur Urol, 49: 1058–1064
  8. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risk of death, cardiovascular events, and hospitilization; N Engl J Med 2004; 351: 1296–305
  9. Huang WC, Levey AS, Serio AM et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006; 7: 735–40
  10. Huang WC et al., J Urol 2009; 181: 55–62. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors: is there a difference in mortality and cardiovascular outcome?
  11. Impact of radical and partial nephrectomy on renal function in patients with renal cancer.
    Krebs RK et al., Urol Int 2014; 92: 449–54
  12. Piper C, Heidenreich A et al. Organerhaltende Nierentumorchirurgie bei Nierenzellkarzinomen ≥T1b. Operationstechnik, Komplikationen und onkologische Kontrolle Urologe 2012, 51: 539–543. DOI 10.1007/s00120-011
  13. Desantis et. al. (Ottawa), CUAJ, January-February 2015, Volume 9, Issues 1-2
  14. Ficarra, V., Novara, G., Secco, S., Macchi, V., Porzionato, A., De Caro, R., & Artibani, W. (November 2009). Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. European Urology, S.786–93
  15. Kutikov, A., & Uzzo, R. (September 2009). The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. The Journal of Urology, S.844–53
  16. Van Poppel H, Da Pozzo L, Albrecht W et al (2011) A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 59(4): 543–52
  17. Crépel M, Jeldres C, Perrotte P et al (2010) Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0 Renal Cell Carcinoma: A Population-based Assessment. Urology, 75: 271–75

Stellenwert der radikalen prostataschonenden Zystektomie in der Therapie des
Harnblasenkarzinoms
(S.18–22)
Axel Heidenreich, Markus Grabbert, Tobias Kohl, David Pfister

  1. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA; European Association of Urology (EAU). Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011 Jun; 59(6): 1009–18
  2. Hautmann RE, de Petriconi RC, Volkmer BG. 25 years of experience with 1,000 neobladders: long-term complications. J Urol. 2011 Jun; 185(6): 2207–12
  3. Studer UE, Burkhard FC, Schumacher M, Kessler TM, Thoeny H, Fleischmann A, Thalmann GN. Twenty years experience with an ileal orthotopic low pressure bladder substitute – lessons to be learned. J Urol. 2006 Jul; 176(1): 161–6
  4. Kassouf W, Hautmann RE, Bochner BH, Lerner SP, Colombo R, Zlotta A, Studer UE. A critical analysis of orthotopic bladder substitutes in adult patients with bladder cancer: is there a perfect solution? Eur Urol. 2010 Sep; 58(3): 374–83
  5. Novara G, Ficarra V, Minja A, De Marco V, Artibani W. Functional results following vescica ileale Padovana (VIP) neobladder: midterm follow-up analysis with validated questionnaires. Eur Urol. 2010 Jun; 57(6): 1045–51
  6. Kessler TM, Burkhard FC, Perimenis P, Danuser H, Thalmann GN, Hochreiter WW, Studer UE. Attempted nerve sparing surgery and age have a significant effect on urinary continence and erectile function after radical cystoprostatectomy and ileal orthotopic bladder substitution. J Urol. 2004 Oct; 172(4 Pt 1): 1323–7
  7. Zippe CD, Raina R, Massanyi EZ, Agarwal A, Jones JS, Ulchaker J, Klein EA. Sexual function after male radical cystectomy in a sexually active population. Urology 2004 Oct; 64(4): 682–5
  8. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol. 2011 Sep 20; 29(27): 3669–76
  9. Vallancien G, Abou El Fettouh H, Cathelineau X, Baumert H, Fromont G, Guillonneau B. Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol. 2002 Dec; 168(6): 2413–7
  10. Damiano R, Di Lorenzo G, Cantiello F, De Sio M, Perdonà S, D'Armiento M, Autorino R. Clinicopathologic features of prostate adenocarcinoma incidentally discovered at the time of radical cystectomy: an evidence-based analysis. Eur Urol. 2007 Sep; 52(3): 648–57
  11. Gakis G, Schilling D, Bedke J, Sievert KD, Stenzl A. Incidental prostate cancer at radical cystoprostatectomy: implications for apex-sparing surgery. BJU Int. 2010 Feb; 105(4): 468–71
  12. Colombo R, Bertini R, Salonia A, Da Pozzo LF, Montorsi F, Brausi M, Roscigno M, Rigatti P. Nerve and seminal sparing radical cystectomy with orthotopic urinary diversion for select patients with superficial bladder cancer: an innovative surgical approach. J Urol. 2001 Jan; 165(1): 51–5
  13. Botto H, Sebe P, Molinie V, Herve JM, Yonneau L, Lebret T. Prostatic capsule- and seminal-sparing cystectomy for bladder carcinoma: initial results for selected patients. BJU Int. 2004 Nov; 94(7): 1021–5
  14. Muto G, Bardari F, D'Urso L, Giona C. Seminal sparing cystectomy and ileocapsuloplasty: long-term followup results. J Urol. 2004 Jul; 172(1): 76–80
  15. Saidi A, Nahon O, Daniel L, Lay F, Lechevallier E, Coulange C. Prostate-sparing cystectomy: long-term functional and oncological results in a series of 25 cases. Prog Urol. 2004 Apr; 14(2): 172–7
  16. Terrone C, Cracco C, Scarpa RM, Rossetti SR. Supra-ampullar cystectomy with preservation of sexual function and ileal orthotopic reservoir for bladder tumor: twenty years of experience. Eur Urol. 2004 Aug; 46(2): 264–9
  17. Martis G, D'Elia G, Diana M, Ombres M, Mastrangeli B. Prostatic capsule- and nerve-sparing cystectomy in organ-confined bladder cancer: preliminary results. World J Surg. 2005 Oct; 29(10): 1277–81
  18. Wunderlich H, Wolf M, Reichelt O, Fröber R, Schubert J. Radical cystectomy with ultrasound-guided partial prostatectomy for bladder cancer: a complication-preventing concept. Urology. 2006 Sep; 68(3): 554–9
  19. Rozet F, Lesur G, Cathelineau X, Barret E, Smyth G, Soon S, Vallancien G. Oncological evaluation of prostate sparing cystectomy: the Montsouris long-term results. J Urol. 2008 Jun; 179(6): 2170-4; discussion 2174–5
  20. Simone G, Papalia R, Leonardo C, Sacco R, Damiano R, Guaglianone S, Forastiere E, Gallucci M. Prostatic capsule and seminal vesicle-sparing cystectomy: improved functional results, inferior oncologic outcome. Urology. 2008 Jul; 72(1): 162–6
  21. de Vries RR, Nieuwenhuijzen JA, van Tinteren H, Oddens JR, Visser O, van der Poel HG, Bex A, Meinhardt W, Horenblas S; Urological Working Group of the Amsterdam Comprehensive Cancer Center. Prostate-sparing cystectomy: long-term oncological results. BJU Int. 2009 Nov; 104(9): 1239–43
  22. Thorstenson A, O'connor RC, Ahonen R, Jonsson MN, Wijkstrom H, Akre O, Hosseini A, Wiklund NP, Henningsohn L. Clinical outcome following prostatic capsule- and seminal-sparing cystectomy for bladder cancer in 25 men. Scand J Urol Nephrol. 2009; 43(2): 127–32
  23. Abdelsalam YM, Mokhtar AA, Kurkar AA, Saleh MA, Elganainy EO. Defining Patient Selection for Prostate-Sparing Cystectomy in Squamous Cell Carcinoma of the Urinary Bladder Associated With Bilharziasis: An Overview of 236 Patients. Urology. 2011 Oct 17. [Epub ahead of print]
  24. Tabibi A, Simforoosh N, Parvin M, Abdi H, Javaherforooshzadeh A, Farrokhi F, Soltani MH. Predictive factors for prostatic involvement by transitional cell carcinoma of the bladder. Urol J. 2011 Winter; 8(1): 43–7
  25. Arce J, Gaya JM, Huguet J, Rodriguez O, Palou J, Villavicencio H. Can we identify those patients who will benefit from prostate-sparing surgery? Predictive factors for invasive prostatic involvement by transitional cell carcinoma. Can J Urol. 2011 Feb; 18(1): 5529–36
  26. Richards KA, Parks GE, Badlani GH, Kader AK, Hemal AK, Pettus JA. Developing selection criteria for prostate-sparing cystectomy: a review of cystoprostatectomy specimens. Urology. 2010 May; 75(5): 1116–20
  27. Mathers MJ, Zumbe J, Wyler S, Roth S, Gerken M, Hofstädter F, Klotz T. Is there evidence for a multidisciplinary follow-up after urological cancer? An evaluation of subsequent cancers. World J Urol 2008 Jun; 26(3): 251–6
  28. Giannarini G, Kessler TM, Thoeny HC, Nguyen DP, Meissner C, Studer UE. Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? Eur Urol. 2010 Oct; 58(4): 486–94
  29. Volkmer BG, Kuefer R, Bartsch GC Jr, Gust K, Hautmann RE. Oncological followup after radical cystectomy for bladder cancer-is there any benefit? J Urol. 2009 Apr; 181(4): 1587–93; discussion 1593
  30. Bochner BH, Montie JE, Lee CT. Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. Urol Clin North Am 2003 Nov; 30(4): 777–89
  31. Kotb A, Aprikian AG. Is sparing the prostate still considered radical cystectomy? The case against prostate-sparing cystectomy for bladder cancer. Can Urol Assoc J. 2009 Dec; 3 (6 Suppl 4): S220–2
  32. Klotz L, Pinthus J. The case for prostate capsule-sparing radical cystectomy in selected patients. Can Urol Assoc J. 2009 Dec; 3 (6 Suppl 4): S215–9
  33. Klotz L. Prostate capsule sparing radical cystectomy: oncologic safety and clinical outcome. Ther Adv Urol. 2009 Apr; 1(1): 43–50

Immuntherapie beim  Nierenzellkarzinom (S.24–26)
Carsten Grüllich

  1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews Cancer. 2012; 12(4): 252–264
  2. Robert J. Motzer, M.D., Bernard Escudier, M.D., David F. McDermott  et. Al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015 Nov 5; 373: 1803–13
  3. Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante et al. Safety and Efficacy of Nivolumab in Combination WithIpilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. J Clin Oncol Jul 5, 2017
  4. Javelin renal 101, NCT02684006; Keynote-426, NCT02853331
  5. D Carl, C Grüllich, S Hering, M Schabet. Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy. BMC Res Notes 2015; 8: 316
  6. K Fritsch, J Finke, C Grüllich. Suppression of granzyme B activity and caspase-3 activation in leukaemia cells constitutively expressing the protease inhibitor 9. Ann Hematol 2013 Dec; 92(12): 1603